Sierra World Equity Review is always on the cutting edge of the latest industry news. Arena Pharmaceuticals is about to have it's obesity weight loss drug Lorcaserin approved this week. Look for Pfizer to makes it move!
Pfizer Ah 8112 8112 Resorb Pkts 64Gm 12- Dis
With it's cholesterol drug, Lipitor patent expired Pfizer is desperately trying to stem the loss of the huge revenues it had garnished for the company. They have been very active buying out four small biotech publicly traded companies in the last few years! They have also spent millions on research and development trying for an obesity weight loss drug without success.
Sierra World Equity Review predicts that Arena Pharmaceuticals will have it's obesity weight loss drug Lorcaserin hydrochloride approved this week by the FDA.
BarCharts- Inc. 9781423203025 Obesity- Adults- Pack of 3
Unfortunately, new drugs are not replacing expiring multi-billion dollar sellers. In fact, just the opposite is true, although it is not due to a lack of effort. For example, Pfizer spent years looking for a replacement for Lipitor, but the replacement candidate, torcetrapib, despite raising HDL, the so-called "good" cholesterol, actually increased death rates during clinical trials, and it was withdrawn. Hundreds of millions of research dollars went down the drain with it. Having failed in other attempts to replenish its pipeline through the discovery process, Pfizer took the "predator" route and bought Wyeth for its product line in 2009.
Thus it makes very good fiscal sense for a giant like Pfizer to move in and sweep up the small successful bio techs like
Arena Pharmaceuticals. BIG WINNERS in the equation will be all the shareholders of ARNA....good for you:)
Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.
